Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 20, 2018

View Archived Issues

Identification and preclinical characterization of ABX-1431, inhibitor of monoacylglycerol lipase

New type of neuronal insulation discovered

Sleeper HIV can be napping or conked out

NOXA gives leg up to BCL-2 inhibition

Immunocore and Genentech enter partnership to codevelop IMC-C103C

NLRP3 antagonist IFM-514 shows promise in mouse models of NASH

SNACing on peptides: findings may allow oral delivery of peptides

Nash Pharmaceuticals reports data on NP-135 in mouse model of kidney fibrosis

Aurigene's small molecule antagonist targets both PD-L1 and TIGIT pathways

Rocket Pharmaceuticals announces FDA clearance of IND for RP-L201 gene therapy

First patients dosed in phase I OPTIC study of ADVM-022 gene therapy in wet AMD

First-in-human results presented for NGM-313 in insulin-resistant obese patients with fatty liver

Samumed doses first subject in phase II/III study of SM-04554

First patient dosed in first-in-human study of NJA-730

French approvals to begin phase II trial of Tedopi and Opdivo in pancreatic cancer

Lunan Pharmaceutical Group presents IDO1 inhibitors

Denali reports promising phase I outcomes with RIPK1 inhibitor DNL-747

New DAT inhibitors may improve effort-related motivation dysfunction

Sentinel Oncology divulges PLK1 inhibitors

Interim phase I results show VLA-1601 induces neutralizing antibodies against Zika virus

Phase III trial of STAGR-320 in house dust mite-induced allergic rhinitis meets primary endpoint

Aviara Pharmaceuticals discloses ITGA4 and LPAM-1 antagonists

Machavert to use grant award to support RAL GTPase inhibitor development

Phase I data on BLU-5937 support progression to phase II for chronic cough

Ohara Pharmaceutical identifies anticancer agents

NIH grant supports IBBR's development of antibody therapeutic against HIV-1

Lupin identifies hSTING agonists for cancer and infections

GeoVax collaborates with Leidos on immunotherapy research program

CPI-818 demonstrates promising safety and efficacy in dogs with T-cell lymphoma

AZD-3229 demonstrates efficacy in preclinical models driven by KIT gene mutations

RSK3 inhibition by gene therapy reduces cardiac dysfunction after myocardial infarction in mice

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...